Vericel Corp Ord is a biotechnology business based in the US. Vericel Corp Ord shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $43.36 – an increase of 0.39% over the previous week. Vericel Corp Ord employs 314 staff and has a trailing 12-month revenue of around $214.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $43.36 |
|---|---|
| 52-week range | $30.18 - $54.10 |
| 50-day moving average | $47.45 |
| 200-day moving average | $45.58 |
| Wall St. target price | $57.14 |
| PE ratio | 4225 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.36 from 2024-10-04
| 1 week (2024-09-30) | 2.63% |
|---|---|
| 1 month (2024-09-06) | -4.11% |
| 3 months (2024-07-05) | -7.11% |
| 6 months (2024-04-05) | -15.10% |
| 1 year (2023-10-06) | 27.19% |
|---|---|
| 2 years (2022-10-07) | 84.59% |
| 3 years (2021-10-07) | 52.19 |
| 5 years (2019-10-07) | 213.07% |
Valuing Vericel Corp Ord stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vericel Corp Ord's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vericel Corp Ord's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4225x. In other words, Vericel Corp Ord shares trade at around 4225x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Vericel Corp Ord's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 million.
The EBITDA is a measure of a Vericel Corp Ord's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $214.5 million |
|---|---|
| Gross profit TTM | $109.8 million |
| Return on assets TTM | -0.7% |
| Return on equity TTM | 0.36% |
| Profit margin | 0.37% |
| Book value | $4.97 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Vericel Corp Ord to pay a dividend over the next 12 months.
Vericel Corp Ord's shares were split on a 1:20 basis on 15 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corp Ord shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corp Ord shares which in turn could have impacted Vericel Corp Ord's share price.
Over the last 12 months, Vericel Corp Ord's shares have ranged in value from as little as $30.18 up to $54.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corp Ord's is 1.685. This would suggest that Vericel Corp Ord's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. .
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.